Skip to content

Author

L. Eichenfield

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Long-Term Safety of Baricitinib in Pediatric Patients With Atopic Dermatitis Aged 2 to <18 Years With Up to 5.2 Years of Exposure

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD...

A. Wollenberg, A. Torrelo, Masanori Ikeda et al. · 0 citations
Review Open access Sep 2026

Therapeutic Education in Atopic Dermatitis Worldwide: Current Practices and Future Pathways—An Update From the Oriented Patient Education Network of the International Society of Atopic Dermatitis (OpenED‐ISAD)

Therapeutic patient education (TPE) is increasingly seen as an essential part of managing atopic dermatitis (AD), helping to connect clinical advice with real‐world adherence. This review aims to summarise current TPE approaches in AD, identify ongoing barriers to adherence, and examine innovations like digital healt...

J. Stalder, H. Aubert, S. Barbarot et al. · 0 citations
Oct 2026

Total IgE Levels Better Predict Atopic Dermatitis Flares Than Disease Severity, and Both Are Reduced by Dupilumab Treatment.

BACKGROUND Elevated IgE levels are common in atopic dermatitis (AD). Although their role in AD pathogenesis is unclear, elevated IgE levels may be associated with disease exacerbation. OBJECTIVE To investigate the association of total IgE and/or disease severity with flares and dupilumab's impact on IgE levels and fl...

Brian S. Kim, Lisa A. Beck, E. Simpson et al. · 0 citations
Oct 2026

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.

Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.

A. Paller, L. Stein Gold, E. Simpson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.